Persistence and Adherence With Topical Glaucoma Therapy - 18/08/11
, David S. Friedman, MD b, Essy Mozaffari, PharmD c, Harry A. Quigley, MD b, Alexander M. Walker, MD, DrPH a
Inquiries to Beth L. Nordstrom, PhD, Ingenix Epidemiology, Riverside Center, Suite 3–120 275 Grove St, Auburndale, MA 02466; fax: 617–244–9669Résumé |
Purpose |
The present study describes the patterns and predictors of treatment persistence and adherence among patients who are diagnosed with glaucoma or as glaucoma suspects (based on claims codes).
Design |
A retrospective cohort study using health insurance claims data.
Methods |
Newly treated individuals with diagnosed glaucoma (n = 3623) and suspect glaucoma (n = 1677) were obtained from healthcare claims data in the Ingenix Research Database. For each of these two diagnostic groups, we calculated the duration of continuous treatment with the initially prescribed medication (persistence) and the prevalence of use of the initial medication at various time points (adherence). Four drug classes were included: β-blockers, ⍺-agonists, carbonic anhydrase inhibitors, and prostaglandin analogs.
Results |
Nearly one half of the individuals who had filled a glaucoma prescription discontinued all topical ocular hypotensive therapy within six months, and just 37% of these individuals recently had refilled their initial medication at three years after the first dispensing. Prostaglandins were associated with better persistence than any other drug class, which was indicated by hazard ratios for discontinuation of prostaglandins compared with β-blockers of 0.40 (95% confidence interval, 0.35–0.44) for diagnosed patients and 0.44 (95% confidence interval, 0.37–0.52) for patients with suspect glaucoma. Prostaglandins showed a similar advantage in adherence. Furthermore, patients with diagnosed glaucoma were more likely to adhere to therapy than patients with suspect glaucoma (relative risk = 1.11; 95% confidence interval, 1.05–1.18).
Conclusion |
Persistence and adherence were substantially better with prostaglandins than with other drug classes, and patients with diagnosed open-angle glaucoma were more likely to adhere to treatment than suspected glaucoma.
Le texte complet de cet article est disponible en PDF.Plan
| Supported by Pfizer through a research contract with Ingenix (B.L.N.;A.M.W.) and through an unrestricted grant to Johns Hopkins University (D.S.F.;H.A.Q.). Pfizer provided support for this study through a research contract with Ingenix (B.N. and A.W.). Pfizer also provided an unrestricted grant to Johns Hopkins University (D.F. and H.Q.). One of the authors (E.M.) is employed by Pfizer; he was involved in the study design, interpretation, and writing only as a member of a steering committee; all final decisions were made by the authors not employed by Pfizer. |
Vol 140 - N° 4
P. 598.e1-598.e11 - octobre 2005 Retour au numéro
Article précédent
- Safety Results of Two Phase III Trials of an Intravitreous Injection of Highly Purified Ovine Hyaluronidase (Vitrase®) for the Management of Vitreous Hemorrhage
- Baruch D. Kuppermann, Edgar L. Thomas, Marc D. de Smet, Lisa R. Grillone, Vitrase for Vitreous Hemorrhage Study Groups ⁎
- Risk Factors for Progression to Penetrating Keratoplasty in Patients With Keratoconus
- Sherman W. Reeves, Sandra Stinnett, Ron A. Adelman, Natalie A. Afshari
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?